Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Researchers report 'promising' ASF vaccine breakthrough
The vaccine was created by deleting a series of genes from the ASF virus.

Chinese teams develop ‘safe and effective’ vaccine

Researchers from China’s Harbin Veterinary Institute have reported that an African Swine Fever (ASF) vaccine has been developed which has proved safe and effective under laboratory testing.

In a research paper published in Science China Life Sciences, the research team stated that the live vaccine was created by deleting a series of genes from the virus using the country’s first ASF strain as a backbone.

The researchers said: “We used the Chinese ASFV HLJ/18 as a backbone to generate six viruses bearing different gene deletions, and found that HLJ/18-7GD, which has seven genes deleted, is fully attenuated in pigs, has a low risk of converting to a virulent strain, and could induce solid protection in pigs against lethal ASFV challenge.

“HLJ/-18-7GD has been fully evaluated and proven to be safe and effective against ASFV. We therefore expect that this vaccine will play an important role in the control of ASFV.”

Safety evaluations showed that, after intramuscular injection, the HLJ/18-7GD virus did not appear in the blood or any other organs, and only remained in the lymph nodes of pigs for a short period. From this, researchers surmised that HLJ/18-7GD is “highly unlikely to convert to a virulent strain during its replication in pigs.”

Testing also found that the vaccine tested safely in pregnant sows and did not cause abortion when administered in the early, middle and late stages of pregnancy, nor limit the rate of piglets born.

Development of the vaccine was overseen by the Chinese Academy of Agricultural Sciences. At present, there has been no estimate given as to when it could be put into production.

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.